T-705; Favilavir
259793-96-9
157.1
C5H4FN3O2
DMF, DMSO
-20°C
Favipiravir is an inhibitor of influenza viruses A, B, and C (IC50s: A = 0.03- 0.20 µg/mL H1N1; 0.01-0.30 H2N2; 0.08-0.48 H3N2; 0.14-0.15 H4N2; 0.24-1.60 H7N2; 0.20-0.82 H5N1; 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.
It displays no cytotoxicity in a variety of cell lines. Selectively inhibits viral RNA-dependent RNA polymerase . Displays activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses. In clinical trials for treatment of SARS-CoV-2.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
